A new hepatitis B drug shows promise as a potential functional cure, allowing some patients to stop treatment while ...

The sneaky virus poses serious health threats if it goes on to become a chronic disease. Clinical trial results suggest a new ...

A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver ...

The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for ...

Bepirovirsen achieved functional cures in about 1 in 5 patients in global trials; FDA review is set for Oct. 26, 2026.

Most people recover from the infection, but it poses great risks for those who don’t. A new drug may cure 1 in 5 of these ...

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of ...

GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly ...

GSK Plc’s experimental hepatitis B drug eliminated all signs of the disease in about one-in-five patients, a new study showed ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis ...

By Bhanvi Satija LONDON, May 28 (Reuters) - GSK said its experimental chronic hepatitis B drug helped nearly one in five ...

Jody Baron and Gabi Fragiadakis discover why some people with chronic Hepatitis B are cured after they're taken off of ...